China Medical System (867) H1 2024 earnings summary

Executive summary

• Turnover for H1 2024 fell 21.7% year-over-year to RMB3,611.1 million, but rose 6.1% sequentially from H2 2023.

• Profit for the period dropped 52.8% year-over-year to RMB903.4 million, but increased 92.8% from H2 2023.

• The company is transitioning to a "New Product Era" with innovative and exclusive products now accounting for 56.1% of revenue.

• Four innovative drugs entered large-scale clinical application, and one new drug (LUMEBLUE) was approved in China.

• The impact of National VBP is being digested, with non-VBP products showing growth.

Financial highlights

• Gross profit decreased 25.2% year-over-year to RMB2,696.5 million; gross margin at 74.7%, down 3.5 ppt.

• Basic EPS dropped 52.3% year-over-year to RMB0.3734.

• Interim dividend per share declared at RMB0.1507, down 51.9% year-over-year.

• Bank balances and cash stood at RMB3,914.4 million as of June 30, 2024.

• R&D expenditures surged 160.4% year-over-year to RMB622.2 million, representing 17.2% of turnover.

Outlook and guidance

• Focus on accelerating commercialization of innovative products and expanding the product pipeline.

• Continued investment in R&D and clinical development, aiming to launch new products annually.

• Plans to strengthen specialty areas and expand in Southeast Asia, leveraging platform business structure.